In acute neonatal conditions like hypoxic-ischemic encephalopathy, standard care dictates placing babies into therapeutic hypothermia blankets within neonatal ICUs for three days. Rather than disrupting established workflows, ReAlta designed its clinical dosing to begin within six to ten hours of birth, administering ten injections at eight-hour intervals during hypothermia before day-four MRI evaluations. This precise alignment preserves standard care while maximizing clinical trial operational feasibility.
Moving into full-time C-suite roles at early-stage biotechs carries immense operational and clinical risk. Both Kia Motesharei and Howard Berman initially joined ReAlta Life Sciences at the board and chairman levels. This vantage point provided unfiltered access to preclinical findings, clinical safety data, intellectual property, and regulatory dynamics, allowing them to perform an exhaustive risk-reward assessment before taking operational helms as COO and CEO.
Acute neonatal disorders do not require massive primary care sales organizations because patient treatment is heavily centralized. Kia Motesharei notes that the entire US market for hypoxic-ischemic encephalopathy is concentrated across approximately 400 neonatal intensive care units (NICUs). This highly localized setting allows an emerging biotech company to map out point-of-sale infrastructure and commercial launch teams with high efficiency years before final drug approval.
Most viruses trigger inflammatory responses, but the astrovirus produces non-inflammatory gastroenteritis. Howard Berman details how isolating a 15-amino-acid peptide from the astrovirus capsid protein yielded pectirazimod. The resulting therapeutic potently suppresses inflammation across two distinct mechanisms at once: binding extracellularly to block the C1 complement pathway while also inhibiting activated neutrophils and myeloperoxidase in acute conditions like HIE.
Measuring clinical efficacy in newborns is difficult because they lack motor or cognitive skills at birth. Kia Motesharei explains that for hypoxic-ischemic encephalopathy (HIE), demonstrating reduced or eliminated brain injury on day-four MRIs offers a viable surrogate marker for accelerated FDA approval. Long-term functional motor and cognitive benchmarks can then be evaluated at two years of age for standard full approval.
When pioneering a therapy in a disease without precedent approvals, regulatory agencies operate on draft guidance. Drawing on his past work at Madrigal developing the first MASH therapy, Kia Motesharei emphasizes that sponsors must proactively engage regulators years ahead of commercialization. High unmet medical needs in rare indications grant agencies regulatory flexibility, allowing companies to collaborate with the FDA to define acceptable surrogate endpoints and approval pathways.
